| 晚期非小细胞肺癌ALK融合基因及其他少见驱动基因阳性靶向治疗进展 |
| |
| 引用本文： | 张权,张树才.晚期非小细胞肺癌ALK融合基因及其他少见驱动基因阳性靶向治疗进展[J].中国肺癌杂志,2017(1):66-72. |
| |
| 作者姓名： | 张权 张树才 |
| |
| 作者单位： | 首都医科大学附属北京胸科医院肿瘤内科,北京,101149 |
| |
| 摘 要： | 靶向治疗是驱动基因阳性的晚期非小细胞肺癌重要的治疗手段之一，这个领域的治疗进展日新月异，包括新靶点的发现，新药物的问世以及靶向联合治疗方案的应用等，同时研究人员也深入地研究了各种靶向药物原发或获得性耐药机制。本综述旨在总结间变淋巴瘤激酶融合基因（anaplastic lymphoma kinase, ALK）及其他少见驱动基因阳性的非小细胞肺癌靶向治疗的新进展。
|
| 关 键 词： | 肺肿瘤 靶向治疗 ALK |
Research Progress of Targeted Therapy for Anaplastic Lymphoma Kinase and Other Rare Driver Genes in Advanced Non-small Cell Lung Cancer |
| |
| Quan ZHANG,Shucai ZHANG.Research Progress of Targeted Therapy for Anaplastic Lymphoma Kinase and Other Rare Driver Genes in Advanced Non-small Cell Lung Cancer[J].Chinese Journal of Lung Cancer,2017(1):66-72. |
| |
| Authors: | Quan ZHANG Shucai ZHANG |
| |
| Abstract: | Targeted therapy was one of the major treatments in advanced non-small cell lung cancer (NSCLC) with positive driver genes. hTis area of research progresses day by day, with novel target discoveries, novel drug development, and use of novel combination treatments. Researchers have also undergone deep investigation about the molecular mechanisms underlying inherent or acquired resistance to these targeted therapies. hTis review aimed to summarize the advanced develop-ments of targeted therapy for anaplastic lymphoma kinase (ALK) and other rare driver genes in NSCLC. |
| |
| Keywords: | Lung neoplasms Targeted therapy ALK |
| 本文献已被 万方数据 等数据库收录！ |
